Grail reported Q1 revenue growth of 28% year over year, driven by continued expansion of its Galleri multi-cancer screening test. Revenue for the quarter reached $40.8 million, with Galleri revenue at $39.8 million and test volume growing 37% to support incremental ordering momentum. Grail said Galleri volume increased 50% year over year to more than 56,000 tests, and it added new prescribers during the quarter as it expands provider and employer-driven ordering pathways. Executives also highlighted a deal with Epic to integrate Galleri ordering into electronic health record systems, with rollout expected in the second half of the year. The company’s update arrived amid ongoing customer scrutiny after preliminary NHS-Galleri results did not hit a primary endpoint related to stage 3 and 4 cancer reduction. Grail said it expects sales follow-up actions once final data is presented at an upcoming oncology meeting. While development services revenue declined year over year, Grail’s commercial emphasis remains centered on scaling ordering workflows across health systems and digital channels.